![](/images/eToro_logo.png)
ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS, creada en 2005 (Estados Unidos de América), a 496 marcas hermanas y 17478 marcas de la competencia. La marca ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS es propiedad de BRISTOL-MYERS SQUIBB COMPANY, una empresa que cotiza en New York. El sector de ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS es Fabricantes de medicamentos.